Aegean in the clear
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The FDA throws out the company’s second attempt at an accelerated approval.